Sylvie Kirscher

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Thomas Aparicio, Olivier Bouché, E. Maillard et al. · Annals of Oncology · 2017 · 79 citations · Full text

Medicine, Oncology, Pharmacology +12

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial

Étienne Brain, C. Mertens, Véronique Girre et al. · Critical Reviews in Oncology/Hematology · 2010 · 59 citations

Medicine, Oncology, Pharmacology +17

Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.

B. Chauvet, C. Félix-Faure, N Lupsascka et al. · Journal of Clinical Oncology · 1994 · 44 citations

Medicine, Oncology, Radiation Oncology +17

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

Thomas Aparicio, Olivier Bouché, E. François et al. · European Journal of Cancer · 2018 · 39 citations

Medicine, Geriatric Medicine, Oncology +11